ArriVent’s phase 3 EGFR inhibitor trial misses primary endpoint, shares plunge 57%

ArriVent BioPharma reported results from its phase 3 Furvent trial, which evaluated firmonertinib, a brain-penetrant EGFR inhibitor, in patients with exon 20 insertion-mutated non-small cell lung cancer.

The study enrolled 398 participants with locally advanced or metastatic disease and compared two doses of firmonertinib against platinum-based chemotherapy as first-line therapy. The high dose achieved a median progression-free survival (PFS) of 11 months, while the control arm recorded 9.5 months. The low dose showed a median PFS of 8.4 months, performing worse than chemotherapy.

Because the trial did not meet its primary endpoint of PFS by blinded independent central review, ArriVent said the data fell short of expectations. The negative readout sent the company’s shares down about 57% in early Nasdaq trading.